Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

Peter L. Toogood; Patricia J. Harvey; Joseph T. Repine; Derek J. Sheehan; Scott N. VanderWel; Hairong Zhou; Paul R. Keller; Dennis J. McNamara; Debra Sherry; Tong Zhu; Joanne Brodfuehrer; Chung Choi; Mark R. Barvian; David W. Fry

doi:10.1021/jm049354h

journal article Mar 02, 2005

Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

Joseph T. Repine Derek J. Sheehan Scott N. VanderWel Hairong Zhou Paul R. Keller Dennis J. McNamara Debra Sherry Tong Zhu

Joanne Brodfuehrer Chung Choi Mark R. Barvian David W. Fry

Journal of Medicinal Chemistry Vol. 48 No. 7 pp. 2388-2406 · American Chemical Society (ACS)

View at Publisher Save 10.1021/jm049354h

Topics

No keywords indexed for this article. Browse by subject →

References

96

[1]

Fisher P. M. Expert. Opin. Investig. Drugs (2003)

[2]

Huwe A. Angew. Chem., Int. Ed. (2003) 10.1002/anie.200200540

[3]

Sherr C. J. Cancer Cell (2002) 10.1016/s1535-6108(02)00102-2

[4]

Fisher P. M Curr. Opin. Drug Discuss. Dev. (2001)

[5]

Webster K. R. Emerging Drugs (2000) 10.1517/14728214.5.1.45

[6]

Fry D. W. Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs (2000)

[7]

Sielecki T. M. J. Med. Chem. (2000) 10.1021/jm990256j

[8]

Mani S. Exp. Opin. Invest. Drugs (2000) 10.1517/13543784.9.8.1849

[9]

Rosania G. R. Exp. Opin. Ther. Pat. (2000) 10.1517/13543776.10.2.215

[10]

Shapiro G. I. Clin. Invest. (1999) 10.1172/jci9054

[11]

Gray N. Curr. Med. Chem. (1999)

[12]

Garrett M. D. Curr. Opin. Genet. Dev. (1999) 10.1016/s0959-437x(99)80015-x

[13]

Barvian M. J. Med. Chem. (2000) 10.1021/jm000271k

[14]

Fry D. W. J. Biol. Chem. (2001)

[15]

Toogood P. L Med. Res. Rev. (2001) 10.1002/med.1021

[16]

Davies T. G. Nat. Struct. Biol. (2002) 10.1038/nsb842

[17]

Dreyer M. K. J. Med. Chem. (2001) 10.1021/jm001043t

[18]

Legraverend M. J. Med. Chem. (2000) 10.1021/jm9911130

[19]

Wang S. (2001)

[20]

Chang Y.-T. Chem. Biol. (1999)

[21]

Imbach P. Bioorg. Med. Chem. Lett. (1999) 10.1016/s0960-894x(98)00691-x

[22]

Gray N. S. Science (1998) 10.1126/science.281.5376.538

[23]

Schow S. R. Bioorg. Med. Chem. Lett. (1997)

[24]

Brooks E. E. The J. Biol. Chem. (1997) 10.1074/jbc.272.46.29207

[25]

Havlíček L. J. Med. Chem. (1997) 10.1021/jm960666x

[26]

Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5

Laurent Meijer, Annie Borgne, Odile Mulner et al.

European Journal of Biochemistry 1997 10.1111/j.1432-1033.1997.t01-2-00527.x

[27]

Veselý J. Eur. J. Biochem. (1994) 10.1111/j.1432-1033.1994.00771.x

[28]

Zaharevitz D. W. Cancer Res. (1999)

[29]

Gussio R. Anti-Cancer Drug Des. (2000)

[30]

Kunick C. Bioorg. Med. Chem. Lett. (2000) 10.1016/s0960-894x(00)00048-2

[31]

Schultz C. J. Med. Chem. (1999) 10.1021/jm9900570

[32]

Kunick C. Bioorg. Med. Chem. Lett. (2000) 10.1016/s0960-894x(00)00048-2

[33]

Sayle K. L. Bioorg. Med. Chem. Lett. (2003) 10.1016/s0960-894x(03)00651-6

[34]

Anderson M. Bioorg. Med. Chem. Lett. (2003) 10.1016/s0960-894x(03)00638-3

[35]

Tang J. Bioorg. Med. Chem. Lett. (2003)

[36]

Misra R. N. Bioorg. Med. Chem. Lett. (2003)

[37]

Misra R. N. Bioorg. Med. Chem. Lett. (2003)

[38]

Mesguiche V. Bioorg. Med. Chem. Lett. (2003) 10.1016/s0960-894x(02)00884-3

[39]

Song Y. Bioorg. Med. Chem. Lett. (2002)

[40]

Kim K. S. J. Med. Chem. (2002)

[41]

Ortega M. A. Bioorg. Med. Chem. Lett. (2002) 10.1016/s0968-0896(02)00069-x

[42]

Furet P. Bioorg. Med. Chem. Lett. (2002)

[43]

Davis S. T. Science (2001) 10.1126/science.291.5501.134

[44]

Sielecki T. M. Bioorg. Med. Chem. Lett. (2001)

[45]

Furet P. J. Comput.-Aided Mol. Des. (2001) 10.1023/a:1011128510728

[46]

Sasaki S. Bioorg. Med. Chem. Lett. (1998)

[47]

Seong Y.-S. Cancer Res. (2003)

[48]

Mettey Y. J. Med. Chem. (2003) 10.1021/jm020319p

[49]

Murthi K. K. Bioorg. Med. Chem. Lett. (2000) 10.1016/s0960-894x(00)00156-6

[50]

Kim K. S. J. Med Chem. (2000)

Showing 50 of 96 references

Cited By

466

Recent advances in multitarget-directed ligands via in silico drug discovery

Krishnaiah Maddeboina, Bharath Yada · 2024

Drug Discovery Today

In silico identification of novel CDK4 inhibitors for retinoblastoma

Mukesh Kumar, Vikas Srivastava · 2024

Chemical Physics Impact

The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study

Ni Made Pitri Susanti, Fransiska Kurniawan · 2024

Scientific Reports

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment

Ni Made Pitri Susanti, Daryono Hadi Tjahjono · 2021

Molecules

Treating cancer with selective CDK4/6 inhibitors

Ben O'Leary, Richard S. Finn · 2016

Nature Reviews Clinical Oncology

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

Patrick J. Roberts, John E. Bisi · 2012

JNCI: Journal of the National Cance...

Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment

Geoffrey I. Shapiro · 2006

Journal of Clinical Oncology

Metrics

466

Citations

96

References

Details

Published: Mar 02, 2005
Vol/Issue: 48(7)
Pages: 2388-2406

Authors

P

Peter L. Toogood